Overweight, Obesity
Conditions
Keywords
Overweight, Obesity, Maridebart cafraglutide, AMG 133
Brief summary
The primary objective of this study is to assess the pharmacokinetics (PK) of AMG 133 after multiple subcutaneous (SC) administrations in participants with overweight or obesity using various dose regimens.
Interventions
DRUGAMG 133
AMG 133 will be administered SC. Dose levels range from A to D lowest to highest.
Sponsors
Amgen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Participant has provided informed consent before initiation of any study-specific activities/procedures. 2. Male or female participants, between 18 and 65 years of age (inclusive) at the time of Screening. 3. Except for obesity, no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia \[e.g., suspicion of Gilbert's syndrome based on total and direct bilirubin\] is not acceptable) as assessed by the Investigator (or designee). Participants with obstructive sleep apnea, controlled hypertension, and/or controlled dyslipidemia on stable therapies will be permitted. Participants with other mild, well-controlled comorbidities may be permitted with approval of the Investigator (or designee) in consultation with the Medical Monitor as appropriate. 4. Body mass index ≥ 27 kg/m\^2 at the time of Screening. 5. Have a stable body weight (\< 5 kg self-reported change) within 3 months before Screening, as assessed by the Investigator (or designee) based on participant self-report. Have not modified diet or adopted any nutritional lifestyle modification for 3 months, as assessed by the Investigator (or designee) based on participant self-report.
Exclusion criteria
1. History or evidence, at Screening or Check-in, of clinically significant disorder, condition, or disease not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion. 2. History of or active diabetes (regardless of type with the exception of gestational diabetes), or Hemoglobin A1C ≥ 6.5% (≥ 48 mmol/mol), at Screening. 3. History or evidence of endocrine disorder (such as Cushing's Syndrome) that can cause obesity. 4. History of acute or chronic pancreatitis within 1 year prior to Check-in, or elevation in serum lipase/amylase (\> 2x the upper limit of normal) at Screening, or fasting serum triglyceride level of \> 500 mg/dL at Screening. One repeat of abnormal values will be allowed. 5. Malignancy except nonmelanoma skin cancers or cervical or breast ductal carcinoma in situ within the last 5 years. 6. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. 7. Uncontrolled thyroid disease, defined as thyroid-stimulating hormone (TSH) \> 6.0 mIU/L or \< 0.4 mIU/L at Screening. Participants who receive treatment for hypothyroidism are permitted if their thyroid hormone replacement dose has been stable for 3 months prior to Screening and TSH criteria are met. 8. History of or current signs of gastroparesis. 9. Previous surgical procedure for obesity within 6 months prior to Check-in. 10. History or current signs or symptoms of cardiovascular disease (aside from controlled hypertension and controlled dyslipidemia), including but not limited to myocardial infarction, congenital heart disease, valvular heart disease, coronary revascularization, or angina. 11. History or evidence of clinically significant arrhythmia at Screening, including any clinically significant findings on the ECG taken at Screening or Check-in. 12. History of hypersensitivity or allergy to AMG 133 or its ingredients, unless approved by the Investigator (or designee) and in consultation with the Sponsor. 13. Estimated glomerular filtration rate less than ≤ 60 mL/min/1.73 m\^2 as calculated by the Modification of Diet in Renal Disease equation at Screening or Check-in. One repeat of abnormal values will be allowed. 14. Alanine aminotransferase or aspartate aminotransferase \> 2x the upper limit of normal at Screening or Check-in. One repeat of abnormal values will be allowed. 15. History of or current suicidal ideation (thoughts), suicide attempt(s), or major psychiatric illness (including depression) within 6 months prior to Screening. 16. Use of any over-the-counter or prescription medications within 30 days or 5 half-lives (whichever is longer) before Check-in. 17. Current use or prior use of any glucagon-like peptide 1 receptor (GLP-1R) agonist, GIPR glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist or antagonist within the past 3 months prior to Check-in. 18. Current or prior use of all herbal medicines (e.g., St. John's wort), vitamins, and supplements consumed by the participant within the 30 days prior to enrollment, unless deemed acceptable by the Investigator (or designee) and in consultation with the Sponsor. 19. Female participants of childbearing potential with a positive pregnancy test assessed at Screening or Check-in by a serum or urine pregnancy test. 20. Female participants lactating/breastfeeding or who plan to breastfeed during the study through 16 weeks after the last dose of AMG 133. 21. Unwilling to adhere to contraceptive requirements through 16 weeks after the last dose of AMG 133. 22. Participant has received a dose of an investigational drug within the past 30 days or 5 half-lives, whichever is longer, prior to Check-in. 23. Have previously completed or withdrawn from this study or any other study investigating AMG 133 or have previously received the investigational product. 24. Unwilling to abide with study restrictions. 25. Participants who, in the opinion of the Investigator (or designee), should not participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum Concentration (Cmax) of AMG 133 | Up to Day 99 |
| Area Under the Plasma Concentration-time Curve from Time Zero to the Last Quantifiable Concentration (AUClast) of AMG 133 | Day 29 |
| Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of AMG 133 | Day 29 |
| Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCtau) of AMG 133 | Day 1 and Day 15 |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants Who Experience Serious Adverse Events | Up to Day 99 |
| Number of Participants Who Develop Anti-AMG 133 Antibodies | Up to Day 99 |
| Number of Participants Who Experience Treatment-emergent Adverse Events | Up to Day 99 |
Countries
United States
Outcome results
None listed